GOG-0279

Terminated

Return to Protocol Table

A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva

Principal Investigator

Neil S. Horowitz

Status

Terminated

Open to Accrual

July 2, 2012

Temporarily Closed to Accrual

June 15, 2015

Open to Accrual

July 25, 2016

Closed to Accrual

February 20, 2020

Closed to Accrual & Treatment

May 1, 2020

Complete

June 1, 2024

Terminated

June 1, 2024


Disease Site

Gynecologic [GY] Other

Phase

II

Developmental Therapeutics

No

Primary Objective

To determine the efficacy of cisplatin, gemcitabine, and Intensity-Modulated Radiation Therapy (IMRT) in achieving a complete pathologic response when used for the primary treatment of locally-advanced squamous cell carcinoma of the vulva. 

Patient Population

Patients with locally-advanced, previously untreated squamous cell T2 or T3 primary vulvar tumors (N0-3,M0) not amenable to surgical resection by standard radical vulvectomy

Target Accrual

52

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.